Jan 21st, 2007, 19:02
|
#1 |
|
Senior Member
   
注册日期: Sep 2005
帖子: 766
  |
【分享】BIO-Tech listed on TSX and TSXV
I just got them from my watchlist , pls add more if you know: AHX.TO MBC.TO PYT.V BNC.TO MBX.TO SVA.V CJB.TO MGI.TO TOX.V EIA.TO MIR.V VAS.TO IZP.TO NDX.V WXI.TO JEN.V ORB.to MBX.TO PLI.TO TH.TO MPH.TO MS.TO CJB.TO NRI.TO BRA.TO IEX.to hae.to Add 2 more : sss.v ixs.v 此帖于 Jan 21st, 2007 20:47 被 Green888 编辑。 |
我是一个新手低手,说股不当之处请大家包涵，希望不要受我误导。
|
|
|
|
|
Jan 26th, 2007, 21:21
|
只看该作者 #6 |
|
Senior Member
注册日期: Nov 2004
帖子: 1,217
积分:2
精华:2
声望: 69630
|
ZT
原文的连接在此： http://web.wenxuecity.com/BBSView.ph...best&MsgID=777 谈谈投资生化股（BIO-TECH）的风险 来源: adventer 于 05-03-05 10  58 [档案] [博客] [旧帖] [转至博客] [给我悄悄话] 自ELN及BIIB其药物医死人消息传出后，两者股价大幅下跌，波及同类。其实，投资生化股的风险比投资一般的科技股的风险更大。生化股在好坏消息的公报时间表上是不定的，尤如一颗炸弹放在身边，随时会爆。而科技股主要好坏消息来源于业绩的报道及预测，时间上可以控制。 生化股的定价是与其对药物的研究及发展到最后获得FDA的认可有一定关系的。一种药物的开发研究到临床试验需要通过三个阶段来完成： 第一阶段：开发研究药物的确立，资金来源，从实验室录取的研究数据等等，都要准备就绪。股价在这一阶段是最原始的，也就是股票市场上的报价。举个例子说，有一个研究项目的，股票报价可能是从几毛到两三块左右，同时有两个或三个的，股票报价可能是八块或十二块。如此类推。 第二阶段：将研究数据用于动物身上的实验。其研究结果以及资金是否充足将决定股价能否上一台阶。如果顺利，股价续涨到20-30左右，否则，股价就被打回原形的几毛。 第三阶段：也就是在对人的临床试验上，这是成功的关键，关系到能否得到FDA的批准。资金能否继续。 这一切又决定了股价能否涨到35-40左右。在这一阶段的失败，会有功亏一篑的危机。股价的下跌幅度比较深。 最后将临床试验数据呈递FDA，如果获得FDA批准，股价会在消息公布后根据市场需求量及竞争程度而大涨。 由于药物在医治病人的过程中，出现的副作用都不相同。倘若出现医死人的状况，该药物就会大打折扣，股价也会遭殃。 以上纯是个人的见解，股价的数字只是举例。仅供参考。 |
|
|
|
|
Jan 30th, 2007, 22:28
|
只看该作者 #8 |
|
Senior Member
注册日期: Sep 2005
帖子: 766
声望: 253766
|
Risk 是 大大的
IZp。TO ----- Oooops today, one more for tomorrow. YM Biosciences halts testing of cancer drug LEONARD ZEHR Globe and Mail Update Shares of drug developer YM Biosciences Inc. are likely to plunge at the opening tomorrow after the drug developer said it has halted late-stage clinical testing of its flagship cancer drug tesmilifene. The Mississauga-based company said it was advised to stop the Phase III trial by an independent Data Safety Monitoring Board because “it is very unlikely significant differences in overall survival will be shown between treatment arms as the data mature.” The trial was not stopped because of safety concerns. “We are very disappointed by this outcome and will be evaluating the data to understand why tesmilifene did not add a clinical benefit in this trial,” said David Allan, chairman and chief executive officer of YM. “Upon completing the review of the Phase III data, the company will consider its options relating to tesmilifene.” Shares of YM closed at $3.46, up 6 cents, on the Toronto Stock Exchange today. The company statement was released after the close of trading. Related to this article Follow this writer Add LEONARD ZEHR to my e-mail alerts Latest Comments Start a conversation on this story The Phase III trial had compared tesmilifene plus chemotherapy against chemotherapy alone in women with metastatic breast cancer. The monitoring board made its decision after an interim analysis. The study had completed enrolment of 723 patients in September, 2005. YM has two other late-stage drugs in development: nimotuzumab, which is being tested in Europe in children with brain cancer, and AeroLEF, a pain killer. |
|
|
|
